Objective-Little is known about the long-term costs of lupus nephritis (LN). These were compared between patients with and without LN based on multistate modelling.
Introduction
Renal disease in SLE patients is associated with significant morbidity and mortality, and is extremely costly (1) . Approximately 40% of SLE patients develop lupus nephritis (LN), although in African descendants and Hispanics of predominantly Amerindian ancestry the frequency may be as high as 60% (2) (3) (4) . Lupus nephritis varies from clinically silent pathology to end-stage renal disease (ESRD), and is often present at the time of SLE diagnosis (2) . The current standard of care includes induction with corticosteroids and mycophenolate mofetil, cyclophosphamide, or rituximab and long-term maintenance therapy with mycophenolate mofetil or azathioprine (5, 6) . Despite receiving treatment according to established guidelines, a significant proportion of patients still progress to ESRD, requiring dialysis or transplantation. Recent studies including a 30-year single centre study (7) indicate that the 5-year risk of ESRD in SLE patients with renal disease ranges between 6.9% to 8.1% and a meta-analysis (8) reports that the 5-year risk of ESRD in those with LN decreased from 16% in the 1970s to 11% in the mid-1990s. These rates have plateaued for at least the past two decades. The presence of renal damage is the most important predictor of early mortality in SLE patients (9) ; in fact, it has been shown that renal damage reduces the survival of SLE patients by approximately 24 years, compared to the general population (10) and LN patients who develop ESRD have a 26-fold increased risk of mortality (11) . Hence, numerous studies demonstrate significantly higher costs in patients with LN versus those without LN (1, (12) (13) (14) .
While SLE patients with renal injury are known to have increased healthcare costs compared to those without renal involvement (15), there is very little data on the long-term healthcare costs of LN patients (12) . Between 1999 and 2011, the Systemic Lupus International Collaborating Clinics (SLICC) enrolled patients into an inception cohort to study long-term clinical outcomes. In previous research on this cohort, reversible multistate modeling has been used to estimate transitions (improvement or deterioration) between multiple states of renal function (16) . This type of modeling is unique in that it provides a dynamic representation of renal dysfunction in continuous time as opposed to the typical static crosssectional view provided by conventional regression analyses. In the current study, multistate modeling was used to forecast the duration in each renal state and the annual direct costs associated with each renal state were calculated. Five and ten-year cumulative costs were then estimated by multiplying the annual costs associated with each renal state with the expected duration in that state and were compared between patients with and without renal involvement. This methodology allows for prediction of costs for renal states in which there are few observations. Understanding how patients progress through states of renal disease and the costs associated with each state will allow for cost-effectiveness analyses of novel emerging therapies.
Patients and Methods

Inception cohort
The SLICC network includes 32 academic centres from 11 countries (17) . Members of this network enrolled patients fulfilling the American College of Rheumatology (ACR) revised classification criteria for SLE (18) into an inception cohort within 15 months of SLE diagnosis (i.e., date at which criteria were met). For this study, data collection extended from 1999 through to 2013. Data were collected at enrollment on demographics (age, sex, race/ ethnicity) and at enrollment and annually (± 6 months) on disease activity [SLE Disease Activity Index -2000 (SLEDAI-2K) (19) ], disease damage [SLICC/ACR Damage Index (SDI) (20) ], smoking history, and alcohol consumption [high risk consumption defined as greater than 10 units per week for females and 15 units per week for males (21) ]. Data were also collected annually on all hospitalizations, medications (including corticosteroids, antimalarials, immunosuppressives, biologics, antihypertensives, lipid-lowering agents, antiepileptics, anti-psychotics and other psychoactive drugs, anticoagulants, and antiplatelets), and dialysis from any time since the previous assessment. The initial focus of the inception cohort was on cardiovascular and neuropsychiatric outcomes and later, on renal outcomes, and as part of the data collection protocol, diagnostic procedures related only to these outcomes were also recorded (e.g. ECGs, echocardiograms, stress tests, neuroimaging, and renal biopsies) and used for resource use and cost estimation. The study was approved by the institutional research ethics review board at each site and each participant provided written informed consent.
Renal status
Lupus nephritis was diagnosed by renal biopsy or fulfillment of the renal item on the ACR classification criteria for SLE (18) . Barber Renal function was also assessed annually based on estimated glomerular filtration rate (eGFR) using the Modification of Diet in Renal Disease (MDRD) equation (22) , or on estimated proteinuria (ePrU) as measured by either 24 hour urine collection or spot urine total protein to creatinine ratio (23) . eGFR was divided into three states: state 1 (eGFR > 60 ml/min), state 2 (eGFR 30-60 ml/min) and state 3 (eGFR < 30 ml/min). ePrU was stratified as: state 1 (ePrU < 0.25 g/d), state 2 (ePrU 0.25-3 g/d), or state 3 (ePrU > 3g/d). End stage renal disease (ESRD) was identified based on the SDI renal variable (20) .
Statistical Analysis
Multistate Modelling-At each assessment, patients were assessed for the presence of LN and state of eGFR and ePrU and were assigned to one of six states in Markov models ( Figure 1 ) for either eGFR or ePrU. Within the eGFR model, it was clinically sensible to assume that a patient could not move from an eGFR state 1 or 2 to ESRD without first having transitioned through eGFR state 3 with LN. However, within the ePrU model, it was clinically reasonable to assume that a patient could develop ESRD from any ePrU state with LN. Further, in both models, direct transition from one state to a non-adjacent state was not permitted in continuous time (except for transition of ePrU state 1 or state 2 with LN to ESRD) and transitions could occur into adjacent higher or lower states, except for ESRD or LN where the transitions were unidirectional. However, changes between non-adjacent states could be observed between assessments, with the transition being assumed to occur through a set of adjacent transitions. Death was regarded as a censoring event consistent with the collection of cost data only in years when death did not occur.
Due to small numbers of transitions into less frequent states, the transition rates between observed states were estimated with a null multistate model without explanatory variables [full details provided in (16) ]. This model can account for intermittent observations and, through conditioning on current states, for the correlation between observations within the same patient. The correlation among the states of a patient at the different assessment visits was characterized through the Markov assumption that the future evolution of a patient's renal function depends only on his/her current state and not on his/her previous history. Transition rates were estimated through maximum likelihood estimation and expected state occupancy times over fixed follow-up periods were also obtained.
Calculating costs-Costs included all hospitalizations, medications, dialysis, and diagnostic procedures related to cardiovascular, neuropsychiatric, and renal manifestations. Costs were calculated from the Canadian national health insurance perspective by multiplying each health resource by its corresponding Canadian unit cost at the 2015 price level. Except for hospitalizations, national estimates for unit costs were based on provincial price data from the Ontario and Quebec Ministries of Health, adjusted to reflect average Canadian prices. The unit cost for medications was sourced from the Quebec List of Medications (published by the Régie de l'assurance maladie du Québec). Reimbursement for physician services related to investigations, dialysis and other procedures was based on the Ontario fee schedule (published by the Ontario Health Insurance Plan), and hospital costs for dialysis and day procedures were sourced from the Ontario Case Costing Initiative (OCCI) (24) . Costs for hospitalizations were developed through the Case-Mix Group method from the Canadian Institute for Health Information (CIHI). This methodology adjusts for the case complexity through resource intensity weights. Appropriate weights were identified using data from previous research on reasons for hospitalizations in a representative sample of lupus patients (25) . Cost per in-patient day was derived from this data, which also incorporated physician reimbursements during hospital stays, based on fee schedules from Ontario and Quebec. Adjustment to average Canadian 2015 price levels was done, in the case of medications, using the Consumer Price Index (http://www.statcan.gc.ca/ tables-tableaux/sum-som/l01/cst01/econ09a-eng.htm) ratio of provincial to national price indices for prescribed medicines, and for all other health services, using similar wage ratios for labour in the healthcare sector across provinces and calendar years (http:// www.statcan.gc.ca/tables-tableaux/sum-som/l01/cst01/health23-eng.htm).
To compute estimates of 5 and 10-year cumulative costs, annual costs associated with each state of renal function, defined as presence of LN and state of eGFR or ePrU or ESRD, were first estimated. Generalized least squares regression modeling with random effects was used to account for possible confounding of the relationship between annual costs and state of renal function. Potential confounding covariates included age, sex, race/ethnicity, geographic region (i.e. within versus outside of North America), disease duration, smoking, and highrisk alcohol use. Adjusted annual cost estimates were predicted using the average values of relevant confounders, and confidence intervals (CI) were calculated using the bootstrapping method, accounting for the non-normal distribution of healthcare costs. Five and ten-year cumulative costs stratified by baseline renal state were calculated by multiplying the adjusted annual cost estimates associated with each renal state by the expected duration in each state over five and ten years. However, accurate discounting of future costs required this calculation to be done for each consecutive year, using expected duration over one-year and repeating the process for longer term estimates. The year-to-year change in state was approximated using transition probabilities estimated after one year. The one-year state durations and transition probabilities were both derived from multistate modelling (16) . Future annual costs for each baseline renal state were discounted at a yearly rate of 3% and annual costs were summed over the five-or-ten year period. Note that since the null multistate model does not include adjustment variables, predicted long-term costs can be compared based on this model, but will only reflect partial adjustment for confounders.
Renal status
Lupus nephritis was diagnosed in 609/1545 patients (39.4%). It was present at enrollment in 466/1545 patients (30.2%) and developed during follow up in another 143/1545 patients (9.3%). 
Annual costs and predictors
Transition probabilities and expected state durations
Based on the estimated transition rates between states, the probability and expected duration for each state of eGFR and ePrU in the absence and presence of LN after 1 year is shown in Table 3 . As anticipated, for example, patients with LN and a baseline eGFR > 60 ml/min (state 1, LN) had a much lower probability of transitioning to ESRD (0.1%) than those with LN and a baseline eGFR < 30 ml/min (state 3, LN) (37.6%). Accordingly, patients with LN and an eGFR > 60 mL/min (state 1, LN) were forecasted to spend none of the next year in ESRD, whereas patients with LN and an eGFR <30 mL/min (state 3, LN) were forecasted to spend one fifth of the next year in ESRD (Table 3 ). Transition probabilities after 1 year and expected state durations over 1 year are also shown for ePrU in Table 3 .
Five and ten-year cumulative costs
Five-year cumulative costs were predicted to be substantially higher in patients with LN and an eGFR < 30 mL/min (state 3, LN) or with ESRD at baseline ( (Table 4 ).
Ten-year cumulative costs were also greater in those with LN and an ePrU of > 3 g/d (state 3, LN) or with ESRD at baseline (Table 4 ).
Discussion
We have provided the first comparison of annual and 5 and 10-year cumulative costs stratified by baseline renal function in an international, multi-ethnic inception cohort of SLE patients. The use of an inception cohort allows for the development of multistate modeling, which can be used to forecast expected duration in each renal state. By incorporating annual costs associated with each renal state, long-term cumulative costs can be estimated stratified by baseline renal status. The regression model examining the association between annual costs and state of renal function produced point estimates of higher annual costs by an average of $870 in non-Caucasians compared to Caucasians in the eGFR model and an average of $789 in the ePrU model, consistent with literature on poorer health outcomes in non-Caucasians (26 However, our study has some limitations. The SLICC network is based within tertiary care academic centres and therefore our patient population may not represent the entire spectrum of SLE patients and likely overestimates the hospitalization, medication, and dialysis costs incurred by SLE patients in a community practice. Further, we did not capture indirect costs due to lost productivity in paid and unpaid endeavors. Additionally, our assessment of healthcare resource utilization was incomplete and therefore we have underestimated total direct costs. While we did capture the most costly components of health resource usehospitalizations, medications, dialysis, and physician visits associated with these services, 
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we did not collect data on other physician or emergency room visits and our assessment of diagnostic procedures was restricted to those related to cardiovascular, neuropsychiatric, and renal disease. Based on our previous work (27) estimating long-term costs for Canadian lupus patients, where all components of direct costs were included, our current estimates would represent, on average, 68% of total direct costs. Our costs were also based only on data that was recorded while patients survived and incurred costs for the whole period preceding questionnaire administration. There were 36 deaths in the study (Supplemental Table 2 ) and because of our study design, we have no data on resource use in the year preceding death.
The substantial cost of LN has been reported by others, primarily through the use of insurance claims databases. Studies from the US have shown that patients with LN incurred annual costs that are 2.5 to 6-fold higher than patients without LN (1, (12) (13) (14) (14) . A Medicaid study reported lower annual costs, but the differential between those with LN and matched controls without SLE was almost 3-fold [$38 401 versus $12 945] (12). These annual costs for patients with LN are substantially higher than our estimates, which range between $3858 and $20 837 depending on the eGFR. However, our cost estimates for ESRD of $ 51 313 are more comparable to the estimates for LN based on insurance data. It is to be expected that our estimates are lower as we did not include all healthcare resources and we used Canadian prices for healthcare, which are much lower than in the US, relative to other consumer goods.
However, use of insurance claims data is limited by reliance on diagnostic codes, which may lead to inclusion of patients who do not have LN, and the lack of detailed data on renal pathology and renal function. Other studies have employed self-reported healthcare utilization in a clinical cohort to estimate the direct costs associated with LN (15), demonstrating almost 5-fold higher costs in ESRD patients compared to SLE patients without any renal damage as defined on the SDI ($144 389 versus $29 499). In our current study, we observed an over 25-fold difference in 5-year costs between those with ESRD and an eGFR > 60 ml/min and no LN ($242 196 versus $9536). This much higher differential in our current study is attributable to two factors: 1) the costs of ESRD are higher in the current study because they are more precise and 2) the costs incurred by patients without renal damage as defined by the SDI are higher than in our current study because these patients were older, had accrued more non-renal damage, and also had renal dysfunction not sufficient to fulfill the SDI renal criteria.
A recent Swedish study estimated both the annual direct and indirect costs of LN compared to all SLE patients by linking well-defined clinical cohorts to national registries and the social insurance system. SLE patients with LN incurred direct costs of $18 579 compared to $13 339 in all SLE patients (28) , with indirect costs comprising approximately 60% of total costs for those with LN and 70% for those without LN. These direct cost estimates for patients with LN are reasonably comparable to ours where annual costs ranged between $3858 and $20 837 for those with LN, but without ESRD.
Unfortunately, the frequency and survival of SLE-related ESRD has not improved over several decades (7, 8, 29, 30) , highlighting the need for new therapies. Although numerous clinical trials of biologics have yielded disappointing results for LN, novel agents continue to emerge, and there is optimism that some will be proven effective (31) . Koutsokeras and Healy (32, 33) forecasted the LN market to be $505 million by 2022 for seven major international markets (United States, France, Germany, Italy, Spain, the United Kingdom, and Japan). As novel biologics become available, understanding the current costs of LN using standard of care is necessary for cost-effectiveness studies. Biologics are very costly, and are often utilized for only refractory or advanced disease. However, they are likely to become more cost-effective over time as their patents expire while the cost of dialysis is unlikely to decrease. Our study demonstrates the substantial cost increases in patients with more advanced renal disease, highlighting the cost savings potentially achieved by earlier aggressive therapy to prevent progression or induce remission of renal disease. 
